A study using wearable scanning technology has revealed how brain function differs in people with multiple sclerosis (MS). It ...

Learn about multiple sclerosis, its symptoms, causes, and treatment options. Understand how early diagnosis helps in managing this neurological condition.

A biology teacher and mother-of-two has become the first UK patient to receive a "gamechanger" therapy to treat multiple ...

Multiple sclerosis, which affects around one in 500 people in Switzerland, is an autoimmune disease in which immune cells attack the central nervous system, causing irreversible damage. Current ...

Researchers have identified two compounds, K102 and K110, that could repair the nerve damage from multiple sclerosis. These drugs help regenerate the protective myelin sheath and balance immune ...

Objective To determine the distribution of the EULAR SSc Impact of Disease (ScleroID) and its domain questions in very early (Ve), limited (lc) and diffuse cutaneous (dc) subsets, its value in ...

Women with relapsing-remitting multiple sclerosis (MS), particularly after menopause, experienced a higher risk of relapse-independent worsening, whereas men showed a greater worsening of disability ...

HENRICO COUNTY, Va. — Walking into Mimi Murdock's Henrico home is a lot like stepping into a painting. "My house, everything's fluid, you know, it's just going to change," Murdock said. "I'm a visual ...

Actor, author and advocate Selma Blair joins TODAY to talk about taking on new projects as she remains “relapse-free” for a couple years from multiple sclerosis. Blair opens up about embarking on new ...

EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...

The EU’s General Court struck down Biogen’s extra year of market protection for Tecfidera, siding with generics in a ruling that could speed cheaper multiple sclerosis drugs to patients. (CN) — ...

New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of ...